Tvardi Therapeutics, Inc. (TVRD) NASDAQ
Currency In USD
AD
- General
- Statistics
- Historical Data
- Profile
- Financials
AD
Currency In USD
Address
3 Sugar Creek Center Boulevard
Sugar Land, TX 77478
United States of America (the)
Phone
832-413-1362
Sector
Healthcare
Industry
Biotechnology
Employees
12
First IPO Date
January 31, 2014
| Name | Title | Pay | Year Born |
| Imran Alibhai | Chief Executive Officer & Director | 942,187 | 1976 |
| Dan Conn | CFO & Corporate Secretary | 603,000 | 1968 |
| John Kauh | Chief Medical Officer | 702,337 | 1974 |
| Jeffrey Larson DABT | Senior Vice President of R&D | 0 | 1962 |
| Michael T. Lewis | Co-Founder & Scientific Advisory Board Member | 0 | N/A |
| David J. Tweardy | Co-Founder & Scientific Advisory Board Member | 0 | N/A |
| Ronald A. DePinho | Co-Founder & Chairman of Scientific Advisory Board | 0 | 1955 |
| Stephen O'Brien | Vice President of Finance & Corporate Controller | 0 | N/A |
| Yixin Chen | Vice President of CMC | 0 | 1961 |
Tvardi Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of novel, oral, and small molecule therapies targeting signal transducer and activator of transcription 3 (STAT3) to treat inflammatory and proliferative diseases with significant unmet need in the United States. The company's lead product candidates include TTI-101, which is in Phase 1b/2 clinical development stage for fibrosis-driven diseases with an initial focus on idiopathic pulmonary fibrosis (IPF), and hepatocellular carcinoma (HCC); and TTI-109, an oral, small molecule STAT3 inhibitor which is in Phase-1 clinical trial stage. Tvardi Therapeutics, Inc. was founded in 2017 and is based in Sugar Land, Texas.